AML-432 Overall survival (OS) by IDH2 mutant allele (R140 or R172) in patients with late-stage, mutant-IDH2 relapsed/refractory acute myeloid leukemia (AML) treated with enasidenib or conventional care regimens (CCR) in the randomized, open-label, Phase 3 IDHENTIFY Trial - DiNardo, CD; de Botton, S; Risueño, A; Schuh, AC; Löwenberg, B; Kim, HJ; Vyas, P; Wei, AH; Stein, EM; Döhner, H; Fathi, AT; Martin-Regueira, P; et al. (Elsevier, 2022)